PROCEPT BioRobotics (PRCT) Cash & Equivalents (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Cash & Equivalents data on file, last reported at $245.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 22.32% year-over-year to $245.6 million in Q1 2026; TTM through Mar 2026 was $245.6 million, a 22.32% decrease from a year earlier, with the FY2025 full-year figure at $275.1 million, down 17.57% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $245.6 million, down from $275.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PRCT reached as high as $333.7 million in Q4 2024 and fell as low as $149.7 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $253.2 million across 5 years, with a median of $257.2 million in 2023.
• Across the five-year window, Cash & Equivalents soared 230.11% in 2022 and sank 44.52% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $221.9 million in 2022, then advanced by 15.94% to $257.2 million in 2023, then advanced by 29.74% to $333.7 million in 2024, then decreased by 17.57% to $275.1 million in 2025, then fell by 10.7% to $245.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $245.6 million in Q1 2026, $275.1 million in Q4 2025, and $294.3 million in Q3 2025.